Tuesday - October 28, 2025
Fortress Biotech Subsidiary Advances Gout Treatment With Dotinurad Phase 3 Trials
October 24, 2025
WASHINGTON, Oct. 24 -- Fortress Biotech, Miami, Florida, and its subsidiary, Urica Therapeutics, have announced the commencement of patient dosing in two randomized, double-blind, multicenter global Phase 3 trials for dotinurad, an investigational treatment for gout. The trials are being conducted by Crystalys Therapeutics, a company in which Urica holds an equity position.

Dotinurad is a next-generation, once-daily oral URAT1 inhibitor being evaluated for its potential in treating . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products